Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-25T00:23:50.088Z Has data issue: false hasContentIssue false

Antiretroviral Drug Resistance Among Patients With Human Immunodeficiency Virus Who Act as Sources or Potential Sources in Occupational Accidents Involving Healthcare Workers

Published online by Cambridge University Press:  21 June 2016

Fabiane El-Far
Affiliation:
Instituto de Infectologia Emilio Ribas, Sao Paulo, Brazil Infection Control Hospital Epidemiology, Federal University of Sao Paulo, Sao Paulo, Brazil
Carlos Teodoro Gasparoto
Affiliation:
Laboratòrio de Retrovirologia, Paulista School of Medicine, Infectious Disease Division, Federal University of Sao Paulo, Sao Paulo, Brazil
Ricardo Sobhie Diaz*
Affiliation:
Laboratòrio de Retrovirologia, Paulista School of Medicine, Infectious Disease Division, Federal University of Sao Paulo, Sao Paulo, Brazil
*
Laboratòrio de Retrovirologia, Infectious Disease Division, Federal University of Sao Paulo, Rua Pedro de Toledo, 781 - 16° Andar. Vila dementino, Sao Paulo, SP, BrazilCEP: 04039-032. , [email protected]

Abstract

Objective:

To determine human immunodeficiency virus (HIV) type 1 genotypic antiretroviral drug resistance profiles of patients presenting a risk or potential risk for occupational exposure of healthcare workers.

Design:

Observational survey involving HIV-infected patients. Blood samples collected from source-patients and potential source-patients underwent HIV-1 genotypic antiretroviral resistance testing and determination of CD4 counts and viral load. Affected healthcare workers were monitored for 6 months after exposure.

Setting:

The survey was conducted in a tertiary-care hospital located in Sao Paulo, Brazil. Sao Paulo is considered the epicenter of the HIV-acquired immunodeficiency (AIDS) virus epidemic in Brazil.

Participants:

Source-patients, potential source-patients, and affected healthcare workers.

Results:

A total of 371 occupational exposures to biological materials were reported, 46 (12.3%) of which were from HIV-seropositive source-patients. Samples from 18 source-patients and 26 patients considered “potential sources for accidents” were analyzed. Of these 44 samples, 18 (41%) presented resistance-related mutations in reverse transcriptase, protease, or both. Of these 18 samples, 16 (89%) had resistance to drugs included in the prophylactic schedule recommended by the Brazilian Ministry of Health.

Conclusions:

Use of the Centers for Disease Control and Prevention-Brazilian post-exposure prophylaxis regimen will result in the administration of antiretroviral agents to which the source HIV-1 isolate will often be resistant. Therefore, it would be advisable to carefully investigate the history of use of antiretroviral agents by source-patients and adjust the prophylactic therapy based on those data and, subsequently, the results of resistance testing.

Type
Original Articles
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Stark, P. Occupational Safety: Selected Cost and Benefit Implications of Needle Stick Prevention Devices for Hospitals. Washington, DC: General Accounting Office; 2000. Publication no. Gao-01-60R.Google Scholar
2.Centers for Disease Control. Acquired immunodeficiency syndrome (AIDS): precautions for health-care workers and allied professionals. MMWR 1982;32:450451.Google Scholar
3.Centers for Disease Control. Public Health Service statement on management of occupational exposure to human immunodeficiency virus, including zidovudine post exposure uses. MMWR 1990;39(RR-1):114.Google Scholar
4.Cardo, DM, Culver, DH, Ciesielski, CA, et al.A case-control study of HIV seroconversion in health care workers after occupational exposure. N Engl J Med 1997;337:14851490.Google Scholar
5.Centers for Disease Control and Prevention. Public Health Service guidelines for the management of health care workers' exposure to HIV and recommendations for post exposure prophylaxis. MMWR 1998;47(RR-7):128.Google Scholar
6.Bottiger, D, Johansson, N-G, Samuelsson, B, et al.Prevention of simian immunodeficiency virus, SIVsm, or HIV-2 infection in cynomolgus monkeys by pre and post exposure administration of BEA-005. AIDS 1997;11:5762.Google Scholar
7.Centers for Disease Control and Prevention. Updated US Public Health Service guidelines for the management of occupational exposure to HBV, HCV and HIV and recommendations for post exposure prophylaxis. MMWR 2001;50(RR-11):142.Google Scholar
8.Kozal, MJ, Shah, N, Shen, N, et al.Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med 1996;2:753759.Google Scholar
9.Jochimsen, EM. Failures of zidovudine post-exposure prophylaxis. Am J Med 1997;102(suppl 5B):5255.Google Scholar
10.Gerberding, JL. Occupational exposure to HIV in health care settings. N Engl J Med 2003;348:826833.Google Scholar
11.Committee Group Members of the Brazilian Government. Ministério da Saúde: Recommendations for the Treatment of HIV Infection in Adults and Adolescents in Brazil—2001. Committee Group Members of the Brazilian Government; 2001. Available at www.aids.gov.br.Google Scholar
12.Frenkel, LM, Wagner, LE II, Aiwood, SM, Cummins, TJ, Dewhurst, S. Specific, sensitive and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine. J Clin Microbiol 1995;33:342347.CrossRefGoogle ScholarPubMed
13.Pieniazek, D, Peralta, JM, Ferreira, JA, et al.Identification of mixed HIV-1/HIV-2 infections in Brazil by polymerase chain reaction. AIDS 1991;5:12931299.Google Scholar
14.Beltrami, EM, Luo, CC, de la Torre, N, Cardo, DM. Transmission of drug resistant HrV after an occupational exposure despite post exposure prophylaxis with a combination drug regimen. Infect Control Hosp Epidemiol 2002;23:345348.Google Scholar
15.Yeni, PG, Hammer, SM, Carpenter, CC, et al.ARV treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society—USA Panel. JAMA 2002;288:222235.Google Scholar
16.Beltrami, EM, Cheingsong, R, Respess, R, Cardo DM. ARV drug resistance in HIV-infected source patients for occupational exposures to healthcare workers. Presented at the 4th Decennial International Conference on Nosocomial and Healthcare Associated Infections and the 10th Annual Meeting of the Society for Healthcare Epidemiology of America; March 5-9, 2000; Atlanta, GA.Google Scholar
17.Track, PC, Bremer, JW, Harris, AA, Landay, AL, Kesseler, HA, Kuritzes, DR. Genotypic analysis of HIV-1 isolates to identify ARV resistance mutations from source patients involved in health care worker occupational exposure. JAMA 1999;281:10851086.Google Scholar
18.Grant, RM, Hecht, FM, Warmerdam, M, et al.Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002;288:181188.Google Scholar